|
|
|
| Bibliometric analysis of thyroid carcinoma in recent ten years#br# |
| CHEN Ying1 LI Xiaoying1 XIA Guanghui1 SHAN Lianhui2 LI Yong2 HOU Li3 |
1.Department of Resource Construction, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing 100005, China;
2.Laboratory of Medical Science and Technology Evaluation, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing 100020, China; 3.Laboratory of Medical Information Standards, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing 100020, China |
|
|
|
Abstract Objective To make a bibliometric analysis of the research status of thyroid carcinoma in recent ten years. Methods CNKI was used as the data source, the journal literatures on thyroid carcinoma published from January 2011 to December 2020 were retrieved as empirical data. Distribution of research subjects, keywords, funds, institutions, the author co-presents situations were analyzed, scientific research network was constructed, prototype system was exploited, and its application of academic social network analysis was described and simulated. Results A total of 6790 journal literatures were included in the analysis. Most of the subjects were thyroid carcinoma and surgery. The core of the most frequent co-occurrence keyword group was thyroid tumor. Most of the supported funds were national nature science foundation of China and provincial natural science foundation. The main publishing institutions were well-known hospitals with many cooperations. Multiple author groups were formed. Conclusion The scope of research subjects is relatively concentrated, frontier researchs are less, multiple scientific research teams with regional characteristics are formed, and the government is the main funding institution of scientific research funds.
|
|
|
|
|
|
[1] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范（2018年版）[J].中华普通外科学文献：电子版，2019， 13（1）：1-15.
[2] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[3] 2020最新全球癌症数据报告[EB/OL].[2021-07-08]. http://med.china.com.cn/content/pid/228924/tid/1026.
[4] 金山.关于分化型甲状腺癌诊治的几点思考[J].中华内分泌外科杂志，2020，14（1）：5-7.
[5] 朱涛，徐洁，田甜，等.2017年美国预防服务工作组甲状腺癌筛查推荐声明解读[J].肿瘤防治研究，2018，45（9）：710-714.
[6] 庞怡，陆征，姜鹏，等.富含碘的饮食与甲状腺癌关系的Meta分析[J].中华地方病学杂志，2017，36（11）：840-845.
[7] Fiore M，Cristaldi A，Okatyeva V，et al. Dietary habits and thyroid cancer risk：A hospital-based case–control study in Sicily（South Italy）[J]. Food Chem Toxicol，2020，146：111778.
[8] 陈晓文，屈宝强，刘蔚，等.基于论文著录信息的基金类别共现分析[J].中华医学图书情报杂志，2018，27（12）：50-57.
[9] 杨珂，林岩松.分化型甲状腺癌钠碘转运体功能的影响因素[J].中华核医学与分子影像杂志，2015，35（6）：512-516.
[10] 杨珂，梁智勇，孟超，等.甲状腺乳头状癌BRAFV600E基因突变与远处转移灶摄碘能力的相关性研究[J].中华核医学与分子影像杂志，2014，34（4）：287-291.
[11] 刘杰蕊，梁军，林岩松.分化型甲状腺癌131I治疗前刺激性Tg与最佳治疗反应的关系[J].中国癌症杂志，2019， 29（2）：125-130.
[12] 胡厚洋，梁军，张腾，等.分化型甲状腺癌被膜及被膜外微小侵犯与复发风险[J].中国癌症杂志，2017，27（12）：946-952.
[13] 胡厚洋，梁军，林岩松.影响分化型甲状腺癌131I治疗获得最佳疗效反应的因素分析及治疗后的动态评估[J].中国肿瘤临床，2018，45（1）：18-21.
[14] 王宸，赵腾，李娇，等.分化型甲状腺癌肺转移131I治疗后早期Tg变化与远期临床转归的关系[J].中华核医学与分子影像杂志，2017，37（9）：555-558.
[15] 鲁涛，高洁，周良锐，等.甲状腺癌RAS/BRAF/TERT基因突变与临床病理特征的关系[J].诊断病理学杂志，2020， 27（4）：250-254.
[16] 梁军，赵丹，梁智勇，等.甲状腺乳头状癌合并淋巴细胞性甲状腺炎临床病理生物学特征分析[J].中华肿瘤防治杂志，2013，20（17）：1331-1335.
[17] Verburg F，Reiners C. Sonographic diagnosis of thyroid cancer with support of AI [J]. Nat Rev Endocrinol，2019， 15（6）：319-321.
[18] 李铃睿，杜博，陈创.人工智能在甲状腺癌精准化诊疗中的研究进展[J].中国肿瘤临床，2020，47（7）：369-374. |
|
|
|
